$21.605
-0.015[-0.07%]
At close: Apr 26
$21.605
0[0.00%]
After Hours: 4:00PM EDT
Silence Therapeutics
(NASDAQ:SLN)Latest News for Silence Therapeutics Stock (NASDAQ:SLN)
Silence Therapeutics Stock (NASDAQ: SLN)
Categories: All
Monday, April 22, 2024
Monday, April 08, 2024
Friday, March 15, 2024
Thursday, March 14, 2024
- These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 ResultsAvi Kapoor - Mar 14, 2024, 2:01PM
- Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $45Benzinga Newsdesk - Mar 14, 2024, 12:33PM
- Chardan Capital Maintains Buy on Silence Therapeutics, Raises Price Target to $42Benzinga Newsdesk - Mar 14, 2024, 7:54AM
Wednesday, March 13, 2024
- What 4 Analyst Ratings Have To Say About Silence TherapeuticsBenzinga Insights - Mar 13, 2024, 4:01PM
- HC Wainwright & Co. Maintains Buy on Silence Therapeutics, Maintains $75 Price TargetBenzinga Newsdesk - Mar 13, 2024, 11:34AM
- What's Going On With Silence Therapeutics Stock Today?Nabaparna Bhattacharya - Mar 13, 2024, 10:16AM
- Silence Therapeutics Reported 2023 Revenue of £25.4M, EPS Loss of £(38.9), Cash Balance of £54.0MBenzinga Newsdesk - Mar 13, 2024, 7:09AM
- Silence Therapeutics Announces Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)Benzinga Newsdesk - Mar 13, 2024, 7:01AM
- Earnings Scheduled For March 13, 2024Benzinga Insights - Mar 13, 2024, 6:15AM
Tuesday, March 12, 2024
Friday, February 23, 2024
Thursday, February 22, 2024
Monday, February 05, 2024
Wednesday, January 31, 2024
- Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On WednesdayAvi Kapoor - Jan 31, 2024, 11:02AM
- Silence Therapeutics shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and $67 price target.Benzinga Newsdesk - Jan 31, 2024, 10:27AM
- BMO Capital Initiates Coverage On Silence Therapeutics with Outperform Rating, Announces Price Target of $67Benzinga Newsdesk - Jan 31, 2024, 6:00AM
Thursday, January 18, 2024
Wednesday, December 13, 2023
Friday, November 17, 2023
Wednesday, November 01, 2023
- Is This A Miracle Drug For 'Sticky Cholesterol'? Analysts Applaud Safety, Efficacy Of Silence Therapeutics' Heart Disease CandidateVandana Singh - Nov 1, 2023, 4:09PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Nov 1, 2023, 1:31PM
- Silence Therapeutics Reports Topline Results From Phase 1 Multiple Dose Study Of Zerlasiran; Lp(a) Levels Remained Around 90% Lower Than Baseline At Study EndpointBenzinga Newsdesk - Nov 1, 2023, 7:12AM
Thursday, August 17, 2023
- HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $80 Price TargetBenzinga Newsdesk - Aug 17, 2023, 12:42PM
- Where Silence Therapeutics Stands With AnalystsBenzinga Insights - Aug 17, 2023, 12:00PM
- Chardan Capital Reiterates Buy on Silence Therapeutics, Maintains $26 Price TargetBenzinga Newsdesk - Aug 17, 2023, 7:47AM
Thursday, August 10, 2023
Monday, July 24, 2023
Monday, July 17, 2023
Monday, June 26, 2023
Tuesday, June 20, 2023
Monday, June 12, 2023
Thursday, May 18, 2023
Tuesday, May 16, 2023
Thursday, May 11, 2023
Monday, May 08, 2023
- Silence Therapeutics shares are trading higher after Morgan Stanley initiated coverage on the stock with an Overweight rating and a $20 price target.Benzinga Newsdesk - May 8, 2023, 11:51AM
- Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023Benzinga Insights - May 8, 2023, 11:00AM
- Morgan Stanley Initiates Coverage On Silence Therapeutics with Overweight Rating, Announces Price Target of $20Benzinga Newsdesk - May 8, 2023, 5:02AM